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ABSTRACT 
Sustained release system is types of modified drug delivery system that can be used as an alternative to conventional system. Among 
different dosage forms, matrix tablets are widely accepted for oral sustained release Metformin hydrochloride has relatively short 
plasma half-life, low absolute bioavailability. The need for the administration two to three times a day when larger doses are 
required can decrease patient compliance. Sustained release formulation that would maintain plasma level for 8-12 h might be 
sufficient for daily dosing of metformin. Sustained release products are needed for metformin to prolong its duration of action and to 
improve patient compliances. They are capable of reducing the dose intake, minimize the blood level oscillation dose related adverse 
effect and cost thus improves the patient compliance in the therapeutic management of diabetes. The Metformin hydrochloride 
matrix Sustained release tablets were prepared using different hydrophilic polymers in various proportions as release retarding agent 
to prolong the drug release and to improve the patience compliance. The tablets were evaluated for various tests like hardness, 
friability, disintegration and in-vitro dissolution studies. 
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INTRODUCTION 
Sustained release system is types of modified drug 
delivery system that can be used as an alternative to 
conventional system. Among different dosage forms, 
matrix tablets are widely accepted for oral sustained 
release1. Sustained release systems have benefits like 
patient compliance, avoidance of multiple dosing, cost 
effectiveness, flexibility, increased plasma drug 
concentration, reduction of side effects; broad regulatory 
acceptance and they overcome the problems associated 
with conventional drug delivery system. Metformin 
hydrochloride an orally administered biguanide, which is 
widely used in the management of and the type -II 
diabetes, is an oral anti-hyperglycemic agent, shows 
incomplete absorption from the gastrointestinal tract and 
the absolute bioavailability is 50 – 60 % with relatively 
short plasma half-life of 1.5 -4.5 h. The aim of this work 
is to prepare matrix tablets containing Metformin 
hydrochloride, as a model drug, using different polymers 
and evaluate its release characteristics. 
1-6
 
MATERIALS AND METHODS 
MATERIALS 
Metformin HCl powder was a gift from USV Ltd, 
Mumbai, India. Microcrystalline cellulose, talc, 
magnesium stearate, polymers such as HPMC and 
sodium alginate were purchased from S. D. Fine Chem. 
Labs. (Mumbai, India). All other ingredients used 
throughout the study were of analytical grade and were 
used as received. 
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METHODS 
 Formulation of sustained release tablet7-9 
Sustained Release Tablets of Metformin HCL with other 
excipients were prepared by direct compression. The 
weight of Metformin HCL was kept constant in all the 
prepared tablets at 400 mg/tablet. Different ratio grades 
of HPMC & SODIUM ALGINATE were chosen as 
polymeric materials. Micro crystalline cellulose (MCC) 
was selected as tablet diluent for increasing the 
compressibility and flowability of the ingredients as well 
as to maintain the tablets at constant weight of 400 mg. 
Magnesium stearate was used as a lubricant at 
concentration of 2% by weight of tablet. To make 
powder mixtures, the drug, polymer and MCC were 
thoroughly mixed for 30 min by means of pestle and 
mortar. This powder mixture was then lubricated with 
magnesium stearate then compressed into tablets in 6 
mm rotary tablet punching machine. The force of 
compression was adjusted so that hardness of all the 
prepared tablets ranges from 5.5-6.5 kg/cm. The detailed 
compositions of the prepared matrix tablets formulations 
are given in (Table no.1) 
 
Table 1: Formulation of sustained released tablet having ratio 1:2 
  
 
 
 
 
 
 
 
Table 2: Formulation of sustained released tablet having ratio 2:1 
 
1) Angle of Repose 10,11 
The angle of repose was determined by fixed funnel 
method. A funnel was kept vertically in a stand at a 
specified height above a paper place on a horizontal 
surface. The funnel was closed was closed and granules 
was filled in funnel. Then funnel was opened to release 
the granules on the paper to form a smooth conical heap. 
The height and radius of heap was measured and the 
angle of repose was calculated by using the following 
formula. 
Ɵ = tan-1 h/r 
Where Ɵ = Angle of repose, h = height of heap and r = 
radius 
Table 3: Relationship between Angle of Repose (Ɵ) 
and flow properties 
Angle of repose (Ɵ) 
(Degrees) 
FLOW 
<25 Excellent 
25-30 Good 
30-40 Passable 
>40 Very poor 
2)  Bulk Density10,11 
A known amount of granules was transferred into a 25-
ml measuring cylindrical carefully level the granules 
without compacting and measure the bulk volume. The 
bulk density was determined by using the formula: 
Bulk Density = Weight of granules / bulk volume 
3) Tapped Density10,11 
Tapped density was determined by digital bulk density 
apparatus. A known amount of granules was transferred 
into the measuring cylinder and tapped upto 100 times 
and measure the tapped volume. The tapped density was 
determined by using the formula: 
Tapped Density = Weight of granules / tapped volume 
4)  Compressibility Index10,11 
Compressibility Index was determined by the following 
formula: 
Compressibility Index =  
[Tapped density – Bulk density / Tapped density]× 100 
S.No. Ingredient Formulation for 
polymer ratio 1:2 
1. Metformin HCL 300 mg 
2. Talc 10 mg 
3. Hydroxypropyl methylcellulose (HPMC) 10 mg 
4. Sodium alginate 20 mg 
5. Magnesium stearate 10 mg 
6. Micro crystalline cellulose (M.C.C.) 50 mg 
S.No. INGREDIENT FORMULATION FOR POLYMER RATIO 2:1 
1. Metformin HCL 300 mg 
2. Talc 10 mg 
3. Hydroxypropyl methylcellulose (HPMC) 20 mg 
4. Sodium alginate 10 mg 
5. Magnesium stearate 10 mg 
6. Micro crystalline cellulose  (M.C.C.) 50 mg 
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Table 4: Relationship between Compressibility Index 
and flow properties 
% CARR’S COMPRESSIBILTY 
INDEX 
FLOW 
5-15 Excellent 
12-16 Good 
18-21 Fair to passable 
23-35 Poor 
33-38 Very poor 
>40 Very 
 
5) Hausner’s Ratio10,11 
Hausner’s ratio was determined by following formula: 
Hausner’s ratio = Tapped density / Bulk density 
6)  Hardness10,11  
In the measurement of hardness, the crushing strength of 
the tablets is measured. It gives the tablets breaking 
force and the strength of the physical tablets are 
represented by the hardness. Hardness was measured 
using a Pfizer hardness tester. Hardness to be measured 
of ten tablets. The hardness were measured in newton. 
The average hardness, relative standard deviation, 
standard deviations were reported. The hardness of the 
tablets were measured during start and between the 
compression. 
7) Weight variation test10,11 
To study weight variation, 20 tablets of each 
formulation were collected randomly during 
compression and weighed using an electronic balance to 
obtain average weight of each tablets. Also, the 
individual tablet was weighted. 
Limit: Weight of individual tablet should be in the limit 
of average weight ±5% 
8) Friability12-14 
The test was carried out using ROCHE FRIABILATOR. 
Ten tablets were taken and carefully dedusted prior to 
testing the tablets were weighed accurately, and placed 
the tablets in the drum. The drum was allowed to be 
rotated 100 times, and after that the tablets were 
removed. Removed loose dust form the tablets as 
before, and weighed accurately. 
The % loss was determined by using following formula: 
             
                         
             
 
A maximum loss of mass not greater than 1.0% is 
considered acceptable. 
9)  Uniformity of drug content12-14 
Five tablets were weighed individually and powdered. 
The powdered equivalent to average weight of tablet 
was weighed and drug was extracted in 0.1 N HCL. 
Undissolved material was filtered out. Filtrate was 
analysed in UV spectrometer at 237 nm after suitable 
dilution. Absorbence value was substituted in the 
equation of standard curve of Metformin HCL 
determined earlier. 
Drug content was calculated by following formula. 
            
                   
                        
       
 
10)   In-vitro Dissolution Studies12-16 
In-vitro drug release study of tablets was performed in 
USP dissolution apparatus Type – 2 (Paddle). The 
dissolution test was performed using 900 ml of 
phosphate buffer 6.8 ph. at 37 ± 0.0.5 ºC with 50 rpm. A 
sample (5 ml) was withdrawn from the dissolution 
apparatus and volume equivalent to the amount of 
sample withdrawn was replaced with fresh dissolution 
dissolution medium. The sample were filtered and 
diluted to suitable concentration with phosphate buffer 
6.8 ph. Absorbances of these solutions were measured at 
237 nm using a UV spectrophotometer. Cumulative 
percentage drug dose was calculated using an equation 
obtained from standard curve. 
11)  In-Vitro Drug Release Kinetic Study 
Kinetic model had described drug dissolution from solid 
dosage form were the dissolved amount of drug is a 
function of test time. In order to study the exact 
mechanism of drug release from the tablet, drug release 
data was analyzed according to zero order, first order, 
Higuchi square root, korsemeyer, Peppas model. The 
regression coefficient R
2
 value nearer to 1 indicating the 
model fitting of the release mechanism. 
 
 
RESULT AND DISCUSSION  
1) Melting Point: The melting point of experimental drug shown in table. 
Table 5: Melting point of drug 
TEST DRUG SPECIFICATION OBERVATION 
Melting point  Metformin HCL 222 -226
0
c 223-227
c
 
 
2) Determination of Wavelength Of Maximum Absorbance  
The wavelength of maximum absorbence (λmax) in 0.1 N HCL was found to be 235 nm and the graph is shown in 
figure. 
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3) Solubility Of Drug  
The solubility of drug in different solvent in shown in 
table. 
Table 6: Solubility of drug in different solvent 
 
S.No. Solvent Solubility 
1 Distilled Water Freely soluble 
2 0.1N HCL Soluble 
3 Ethanol (95%) Slightly soluble 
4 Methylene chloride Practically insoluble 
5 Acetone Practically insoluble 
  
  
4)  Calibration Curve  
 
 
 
Figure 1: Calibration curve of Metformin on 0.01N 
HCL
 
5) Evaluation of precompression parameters 
Table 7: Evaluation of precompression parameters 
 
 
 
6.  Evaluation of post compression parameter 
The results of post compression parameters such as hardness, Friability, Weight variation and Drug content uniformity 
are shown in table. 
Table 8: Result of post compression parameters of formulation 
 
1) In Vitro Dissolution Study:The results obtaining in vitro release studies were plotted Cumulative % release 
against time. These results indicated that the release rate was limited by the drug particles dissolution rate and erosin of 
the different polymer ratio. 
 
Parameters Hydrophilic Formulations 
Polymer ratio 1:2 Polymer Ratio 2:1 
Carss’s Index (%) (n = 3) 5.00±0.02 2.44±0.06 
Hausner'sRatio(n=3)               1.052±0.06 1.025±0.08 
Angle of Repose(n=3)              33.69±0.09 35.31±0.04 
Length(mm)(n=20) 15.088±0.03              15.136±0.01 
Hardness(kP)(n=20)                      33.2±0.01 33.2±0.08 
Weight(mg)(n=20) 399.4±0.04 401.8±0.02 
Thickness(mm)(n=20) 8.096±0.06 8.152±0.01 
Friability (%) (n=10) 0.0197±0.03  0.107±0.06 
ContentUniformity (%) (n=20) 100.268±0.05 100.315±0.04 
Batches Hardness (kg/cm
2)
 Friability (%) Weight Variation Drug Content 
Uniformity 
F1 12.4 0.70 Passes 90.12 
F2 14.52 0.66 Passes 92.65 
F3 15 0.62 Passes 96.15 
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Figure 2: Dissolution Profile of Formulations 
 
    Table 9: Release kinetic Study 
 
 
 
 
 
 
 
 
 
 
 
2) Kinetic Release  Study 
 Kinetics of Metformin Hydrochloride sustained 
released formulation: 
The optimized batch F6 was subjected to graphical 
treatment to assess the kinetic of drug release from 1:2 
polymer ratio tablet. The optimized formulation F6 was 
subjected to Zero order, first order, Hixson-Crowell, 
Higuchi and Korsmeyer-Peppas model to study the in 
vitro kinetic release mechanism. 
From, in vitro kinetic release mechanism study it was 
found that the drug released kinetic of the sustained 
release formulation of optimized batch F6 follow 
diffusion mechanism for drug release from the 1:2 
polymer ratio tablet. 
 
Table 10: Zero order kinetic Model 
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Invitro Drug Release Of Metformin 
Hydrochloride Batches F1, F2, F3 
F1 F2 
 
Time 
(hrs.) 
% Drug Release 
Batch No. 
F1 F2 F3 
Marketed Drug Polymer Ratio  2:1 Polymer Ratio  1:2 
1 40.85 28.79 23.14 
2 59.21 44.63 42.25 
3 70.68 55.16 53.67 
4 85.53 68.25 64.03 
6 94.12 82.32 78.89 
8 96.23 92.57 87.76 
10 97.45 95.27 93.86 
S. No. Time in   hour Cum.% Drug release 
1. 0.5 11.6 
2. 1 26.13 
3. 2 42.26 
4. 3 53.77 
5. 4 64.02 
6. 6 79.31 
7. 8 87.56 
8. 10 93.68 
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Table 11: First order kinetic Model 
 
 
Figure 3: First order kinetic Model 
 
 
Figure 4: Zero order kinetic Model 
 
CONCLUSION 
The present work deals with the aim to formulate and 
evaluate the sustained release tablet of Metformin HCL. 
From results obtained, it was concluded that the 
formulation of sustained release tablet of Metformin 
HCL containing hydrophilic polymers HPMC and 
sodium alginate were capable of exhibiting sustained 
release properties They are capable of reducing the does 
intake minimize the blood level oscillation does related 
adverse effect and cost thus improves the patient 
compliance in the therapeutic management of diabetes.
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S. No. Time in hour 
Log Cum.% Drug 
retained 
1. 0.5 1.946 
2. 1 1.868 
3. 2 1.761 
4. 3 1.664 
5. 4 1.556 
6. 6 1.315 
7. 8 1.094 
8. 10 0.801 
